Prevention of chemotherapy related neutrophilic granulocytic deficiency
Conditions
Interventions
Case series:Mecapegfilgrastim Injection
Sponsors
Baotou Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with breast cancer confirmed by histopathology should be treated with neoadjuvant chemotherapy or adjuvant chemotherapy, which is suitable for the chemotherapy regimen prescribed in this study; 2. Patients satisfy one of the following conditions: patients with grade III/IV neutropenia in previous chemotherapy cycles have planned to use the same regimen in subsequent cycles; patients with FN risk > 20% have chosen the regimen, and patients with FN risk of 10-20% have more than one risk factor; 3. hematopoietic function is normal, no bleeding tendency (INR<1.5); 4. laboratory tests should be consistent with: 1) blood routine examination: Hb=90g/L; WBC=4 x 10^9/L; ANC=2 x 10^9/L; PLT=100 x 10^9/L. 2) liver function and biochemistry examination: ALT and AST=1.5 x ULN; TBIL=1.5 x ULN; serum creatinine=1.5 x ULN. 5. judged by the researchers, they can observe the test plan; 6. the volunteers voluntarily joined the study, signed informed consent, and had good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. pregnant or lactating women; 2. there are other hematological diseases that affect hematopoietic function of bone marrow; 3. allergy to research agents or other G-CSF products and biological agents expressed by E. coli; 4. according to the researchers, there are serious diseases that endanger the safety of patients or affect the completion of research; The researchers judged that other circumstances were not suitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduce the incidence of the first cycle of 3 and 4 degrees ANC by sulphur group.; | — |
Secondary
| Measure | Time frame |
|---|---|
| the incidence of 3 and 4 degree ANC reduction started with the second cycle of sulphur;Incidence of febrile neutropenia (FN) during the use of sulphfefevertin;Proportion of antibiotics used during treatment;The incidence of adverse reactions during the period of chemotherapy with sulphur and FGM; | — |
Countries
China
Contacts
Public ContactZhu Jingjun
Baotou Cancer Hospital
Outcome results
None listed